| |
| |
| Preface to the Second Edition | |
| |
| |
| |
| Introduction to Pharmacodynamics and Pharmacokinetics | |
| |
| |
| Pharmacodynamics | |
| |
| |
| Ligands and Receptors | |
| |
| |
| Neurotransmitters and Signal Transduction | |
| |
| |
| |
| Drug mechanism of action (pharmacodynamics) | |
| |
| |
| Pharmacokinetics | |
| |
| |
| Absorption | |
| |
| |
| Distribution | |
| |
| |
| Elimination | |
| |
| |
| Drug Metabolism | |
| |
| |
| General Issues | |
| |
| |
| Cytochrome Families | |
| |
| |
| |
| Selected substrates, inhibitors, and inducers of major cytochrome P450 enzymes | |
| |
| |
| Glucuronidation | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| Conclusion | |
| |
| |
| References | |
| |
| |
| |
| Antidepressants | |
| |
| |
| Overview | |
| |
| |
| Drug Class | |
| |
| |
| Indications | |
| |
| |
| Mechanisms of Action | |
| |
| |
| Pharmacokinetics | |
| |
| |
| Main Side Effects | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| Use in Special Populations | |
| |
| |
| Tables | |
| |
| |
| Drug Class | |
| |
| |
| |
| Classification of antidepressants by putative neurotransmitter effects | |
| |
| |
| |
| Non-MAOI antidepressants: formulations, strengths, and usual maintenance dosage | |
| |
| |
| |
| Monoamine oxidase inhibitors (MAOIs): tablet strengths and usual adult dosage | |
| |
| |
| |
| Relative monthly cost of selected antidepressants (low/middle therapeutic dosage range) | |
| |
| |
| Indications | |
| |
| |
| |
| "Off-label" and non-mood disorder indications for antidepressants | |
| |
| |
| Mechanisms of Action | |
| |
| |
| |
| Neurotransmitter effects of selected antidepressants | |
| |
| |
| |
| Effects of reuptake blockade and receptor antagonism | |
| |
| |
| |
| Effects of serotonin (5-HT) receptor stimulation | |
| |
| |
| Pharmacokinetics | |
| |
| |
| |
| Pharmacokinetics of selected antidepressants | |
| |
| |
| |
| Pharmacodynamic and pharmacokinetic profiles of newer antidepressants | |
| |
| |
| |
| Putative optimal plasma levels for tricyclic antidepressants | |
| |
| |
| Main Side Effects | |
| |
| |
| |
| Side-effect profiles of commonly used antidepressants | |
| |
| |
| |
| Side effects of tricyclic vs. selected nontricyclic antidepressants (% of patients reporting, placebo adjusted) | |
| |
| |
| |
| Cardiac and autonomic side effects of selected antidepressants | |
| |
| |
| |
| Gastrointestinal and sexual side effects of selected antidepressants | |
| |
| |
| |
| Neurobehavioral side effects of selected antidepressants | |
| |
| |
| |
| Some comparative side effects of selective serotonin reuptake inhibitors (placebo-adjusted %) | |
| |
| |
| |
| Basic management of antidepressant side effects | |
| |
| |
| |
| Selected co-prescribed agents for antidepressant-induced sexual dysfunction | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| |
| Drug-drug interactions with tricyclic antidepressants (TCAs) | |
| |
| |
| |
| Some drugs used in clinical practice that may interact with selective serotonin reuptake inhibitors (SSRIs) and related antidepressants | |
| |
| |
| |
| Drug-drug interactions with monoamine oxidase inhibitors (MAOIs) | |
| |
| |
| |
| Food restrictions for patients taking conventional monoamine oxidase inhibitors (MAOIs) | |
| |
| |
| |
| The serotonin syndrome: differential diagnosis | |
| |
| |
| |
| Serotonin syndrome | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| |
| Agents used to potentiate or augment antidepressants | |
| |
| |
| |
| Psychostimulants and related agents: main features | |
| |
| |
| Use in Special Populations | |
| |
| |
| |
| Selection of nontricyclic antidepressants for patients with special needs or comorbid conditions | |
| |
| |
| |
| Antidepressant dosing in children and adolescents | |
| |
| |
| Questions and Answers | |
| |
| |
| Drug Class | |
| |
| |
| Indications | |
| |
| |
| Mechanisms of Action | |
| |
| |
| Pharmacokinetics | |
| |
| |
| Main Side Effects | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| Use in Special Populations | |
| |
| |
| Vignettes/Puzzlers | |
| |
| |
| References | |
| |
| |
| |
| Antipsychotics | |
| |
| |
| Overview | |
| |
| |
| Drug Class | |
| |
| |
| Indications | |
| |
| |
| Mechanisms of Action | |
| |
| |
| Pharmacokinetics | |
| |
| |
| Main Side Effects | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| Use in Special Populations | |
| |
| |
| Tables | |
| |
| |
| Drug Class | |
| |
| |
| |
| Dosages and putative therapeutic levels of currently available antipsychotics | |
| |
| |
| |
| First-generation ("typical" or "neuroleptic") antipsychotic dosage equivalents of 10 mg of haloperidol | |
| |
| |
| |
| Second-generation ("atypical") antipsychotic dosage equivalents of 10 mg of haloperidol | |
| |
| |
| |
| Comparative costs of some atypical antipsychotics | |
| |
| |
| Indications | |
| |
| |
| |
| Indications for use of antipsychotics | |
| |
| |
| Mechanisms of Action | |
| |
| |
| |
| Relative receptor affinities of haloperidol versus available atypical agents | |
| |
| |
| Pharmacokinetics | |
| |
| |
| |
| Pharmacokinetic profiles of first-generation (neuroleptic) antipsychotics | |
| |
| |
| |
| Pharmacokinetic profiles of second-generation (atypical) antipsychotics | |
| |
| |
| Main Side Effects | |
| |
| |
| |
| Comparative side effects among available first-generation (typical) antipsychotics | |
| |
| |
| |
| Comparative side effects among selected second-generation (atypical) antipsychotics | |
| |
| |
| |
| Motor and mental symptoms of neurolepticinduced extrapyramidal side effects | |
| |
| |
| |
| Selected agents for treatment of extrapyramidal side effects (EPS) of first-generation (neuroleptic) antipsychotics | |
| |
| |
| |
| Neuroleptic malignant syndrome (NMS): differential diagnosis | |
| |
| |
| |
| Management of antipsychotic (AP) side effects | |
| |
| |
| |
| Clozapine and white blood cell count (WBC): managing abnormalities | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| |
| Antipsychotic (AP) drug interactions | |
| |
| |
| |
| Second-generation (atypical) antipsychotics (APs): potential drug-drug interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| |
| Potentiation of antipsychotics (APs) | |
| |
| |
| Use in Special Populations | |
| |
| |
| |
| Antipsychotics (APs) in special populations | |
| |
| |
| Questions and Answers | |
| |
| |
| Drug Class | |
| |
| |
| Indications | |
| |
| |
| Mechanisms of Action | |
| |
| |
| Pharmacokinetics | |
| |
| |
| Main Side Effects | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| Use in Special Populations | |
| |
| |
| Vignettes/Puzzlers | |
| |
| |
| References | |
| |
| |
| |
| Anxiolytics and Sedative-Hypnotics | |
| |
| |
| Overview | |
| |
| |
| Drug Class | |
| |
| |
| Indications | |
| |
| |
| Mechanisms of Action | |
| |
| |
| Pharmacokinetics | |
| |
| |
| Main Side Effects | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| Use in Special Populations | |
| |
| |
| Tables | |
| |
| |
| Drug Class | |
| |
| |
| |
| Commonly used benzodiazepine anxiolytics | |
| |
| |
| |
| Commonly prescribed benzodiazepine and nonbenzodiazepine hypnotics | |
| |
| |
| |
| Nonbenzodiazepine anxiolytics and hypnotics | |
| |
| |
| |
| Dosage and cost of selected benzodiazepines | |
| |
| |
| Indications | |
| |
| |
| |
| Indications for benzodiazepines (BZDs) | |
| |
| |
| |
| Selective serotonin reuptake inhibitors (SSRIs) or related antidepressants with FDA-approved labeling for use in treating DSM-IV-TR anxiety disorders | |
| |
| |
| |
| Off-label uses for beta-blockers and clonidine for anxiety/agitation in selected disorders | |
| |
| |
| Mechanisms of Action | |
| |
| |
| |
| Effect of various agents on GABA[subscript A] receptors | |
| |
| |
| |
| Pharmacodynamic aspects of hypnotic agents | |
| |
| |
| Pharmacokinetics | |
| |
| |
| |
| Pharmacokinetics of orally administered benzodiazepine anxiolytics | |
| |
| |
| |
| Pharmacokinetics of benzodiazepine hypnotics | |
| |
| |
| |
| Pharmacokinetics of nonbenzodiazepine hypnotics | |
| |
| |
| |
| Simplified metabolic pathways of benzodiazepines | |
| |
| |
| Main Side Effects | |
| |
| |
| |
| Frequency (%) of benzodiazepine (BZD) and buspirone side effects (average for various BZDs) | |
| |
| |
| |
| Side effects and management of benzodiazepines (BZDs) | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| |
| Benzodiazepine (BZD) drug interactions | |
| |
| |
| |
| Nonbenzodiazepine (non-BZD) hypnotic drug interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| |
| Agents used in combination with benzodiazepines (BZDs) for augmentation of effect | |
| |
| |
| Use in Special Populations | |
| |
| |
| |
| Potential concerns of benzodiazepine (BZD) use during pregnancy | |
| |
| |
| |
| Risks of benzodiazepine (BZD) use in elderly and/or dementia patients | |
| |
| |
| Questions and Answers | |
| |
| |
| Drug Class | |
| |
| |
| Indications | |
| |
| |
| Mechanisms of Action | |
| |
| |
| Pharmacokinetics | |
| |
| |
| Main Side Effects | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| Use in Special Populations | |
| |
| |
| Vignettes/Puzzlers | |
| |
| |
| References | |
| |
| |
| |
| Mood Stabilizers | |
| |
| |
| Overview | |
| |
| |
| Drug Class | |
| |
| |
| Indications | |
| |
| |
| Mechanisms of Action | |
| |
| |
| Pharmacokinetics | |
| |
| |
| Main Side Effects | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| Use in Special Populations | |
| |
| |
| Tables | |
| |
| |
| Drug Class | |
| |
| |
| |
| Selected mood stabilizers: preparations, usual daily doses, and putative therapeutic blood levels | |
| |
| |
| Indications | |
| |
| |
| |
| Indications for lithium | |
| |
| |
| |
| Preferred treatments of acute manic or mixed episodes in bipolar disorder | |
| |
| |
| |
| Preferred treatments of acute depressive episodes in bipolar disorder | |
| |
| |
| |
| Preferred treatments of rapid cycling in bipolar disorder | |
| |
| |
| |
| Preferred maintenance treatments in bipolar disorder | |
| |
| |
| Mechanisms of Action | |
| |
| |
| |
| Mood stabilizer and anticonvulsant mechanisms of action | |
| |
| |
| Pharmacokinetics | |
| |
| |
| |
| Pharmacokinetics of selected mood stabilizers | |
| |
| |
| Main Side Effects | |
| |
| |
| |
| Lithium side effects | |
| |
| |
| |
| Stages of lithium toxicity | |
| |
| |
| |
| Five most common side effects of carbamazepine | |
| |
| |
| |
| Management of common anticonvulsant mood stabilizer side effects (non-placeboadjusted rates) | |
| |
| |
| |
| Management of lithium side effects | |
| |
| |
| |
| Potential risk factors for antidepressant-induced mania (AIM) or cycling | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| |
| Drug-drug interactions with lithium | |
| |
| |
| |
| Drug-drug interactions with carbamazepine (CBZ) | |
| |
| |
| |
| Drug-drug interactions with valproate | |
| |
| |
| |
| Drug-drug interactions with lamotrigine | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| |
| Augmenting strategies in treating patients with bipolar disorder | |
| |
| |
| Use in Special Populations | |
| |
| |
| |
| Use of mood stabilizers in special populations | |
| |
| |
| Questions and Answers | |
| |
| |
| Indications | |
| |
| |
| Mechanisms of Action | |
| |
| |
| Pharmacokinetics | |
| |
| |
| Main Side Effects | |
| |
| |
| Drug-Drug Interactions | |
| |
| |
| Potentiating Maneuvers | |
| |
| |
| Use in Special Populations | |
| |
| |
| Vignettes/Puzzlers | |
| |
| |
| References | |
| |
| |
| CME Questions and Answers | |
| |
| |
| Index | |